Clean Harbors (CLH)
(Delayed Data from NYSE)
$193.13 USD
-0.87 (-0.45%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $193.14 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CLH 193.13 -0.87(-0.45%)
Will CLH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CLH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLH
Waste Management (WM) Tops Q1 Earnings Estimates
Earnings Preview: Clean Harbors (CLH) Q1 Earnings Expected to Decline
CLH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Montrose Environmental (MEG): Can Its 12.8% Jump Turn into More Strength?
Reasons to Hold Clean Harbors (CLH) in Your Portfolio Now
Why Investors Need to Take Advantage of These 2 Business Services Stocks Now
Other News for CLH
Analyst Issues Sell Rating for Cardinal Health Amid Major Contract Loss and Revenue Decline Concerns
Cardinal Health Faces Earnings Uncertainty Post OptumRx Contract Loss: Analyst Holds Rating
Maintaining a Buy Rating: Cardinal Health’s Strong Fundamentals and Growth Prospects Despite OptumRx Contract Loss
Cardinal Health Announces New Business Structure and Segments
Clean Harbors to Participate in Upcoming Investor Conferences